AffiliationUniversity of Leeds, St James' University Hospital, Leeds, UK. email@example.com
MetadataShow full item record
AbstractPURPOSE OF REVIEW: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. RECENT FINDINGS: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. SUMMARY: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.
CitationNew therapeutic agents in ovarian cancer. 2009, 21 (1):44-53 Curr. Opin. Obstet. Gynecol.
JournalCurrent Opinion in Obstetrics & Gynecology
- Targeted agents in ovarian cancer.
- Authors: Kristedja TS, Morgan RJ, Cristea M
- Issue date: 2010 Sep
- Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Authors: Dhillon S
- Issue date: 2013 Aug
- New drugs for ovarian cancer.
- Authors: Kaye SB
- Issue date: 2008 Feb
- Angiogenesis inhibitors for the treatment of ovarian cancer.
- Authors: Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J
- Issue date: 2011 Sep 7
- Angiogenesis as a target for the treatment of ovarian cancer.
- Authors: Shaw D, Clamp A, Jayson GC
- Issue date: 2013 Sep